Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: A prospective cohort study

Journal of the American Academy of Dermatology

Volumn 75, Issue 3, 2016, Pages 516-524

  Podlipnik, Sebastian ^a,b   Carrera, Cristina ^a,b   Sánchez, Marcelo ^a   Arguis, Pedro ^a   Olondo, Maria L ^a   Vilana, Ramon ^a   Rull, Ramon ^a   Vidal Sicart, Sergi ^a   Vilalta, Antonio ^a   Conill, Carles ^a   Malvehy, Josep ^a,b   Puig, Susana ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

computed tomography scan; follow up; magnetic resonance imaging; melanoma; melanoma inhibitory activity; recurrences; S100B; ultrasonography

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER RECURRENCE; CANCER STAGING; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST; FEMALE; FOLLOW UP; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRIMARY TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; SELF EXAMINATION; SURVIVAL ANALYSIS; THORAX RADIOGRAPHY; BLOOD EXAMINATION; DISEASE FREE SURVIVAL; LYMPH NODE; MEDICAL SOCIETY; MELANOMA; MIDDLE AGED; MORTALITY; MULTIMODAL IMAGING; OUTCOME ASSESSMENT; PATHOLOGY; PHYSIOLOGIC MONITORING; PROCEDURES; RISK ASSESSMENT; SKIN NEOPLASMS; UNITED STATES;

ADULT; AGED; COHORT STUDIES; DIAGNOSTIC TESTS, ROUTINE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC TESTS; HUMANS; LYMPH NODES; MALE; MELANOMA; MIDDLE AGED; MONITORING, PHYSIOLOGIC; MULTIMODAL IMAGING; OUTCOME ASSESSMENT (HEALTH CARE); PHYSICAL EXAMINATION; PROSPECTIVE STUDIES; RISK ASSESSMENT; SELF-EXAMINATION; SKIN NEOPLASMS; SOCIETIES, MEDICAL; SURVIVAL ANALYSIS; UNITED STATES;

EID: 84967222072     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2016.02.1229     Document Type: Article

References (41)

1. Burnet, N.G., Jefferies, S.J., Benson, R.J., Hunt, D.P., Treasure, F.P., Years of life lost (YLL) from cancer is an important measure of population burden–and should be considered when allocating research funds. Br J Cancer 92:2 (2005), 241–245.
2. Lens, M.B., Dawes, M., Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 150:2 (2004), 179–185.
3. Puig, S., Marcoval, J., Paradelo, C., et al. Melanoma incidence increases in the elderly of Catalonia but not in the younger population: effect of prevention or consequence of immigration?. Acta Derm Venereol 95 (2015), 422–426.
4. McDermott, D., Lebbé, C., Hodi, F.S., et al. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev 40:9 (2014), 1056–1064.
5. Brahmer, J.R., Tykodi, S.S., Chow, L.Q.M., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:26 (2012), 2455–2465.
6. Topalian, S.L., Hodi, F.S., Brahmer, J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:26 (2012), 2443–2454.
7. Flaherty, K.T., Robert, C., Hersey, P., et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:2 (2012), 107–114.
8. Wolchok, J.D., Kluger, H., Callahan, M.K., et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:2 (2013), 122–133.
9. Hamid, O., Robert, C., Daud, A., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:2 (2013), 134–144.
10. Leiter, U., Buettner, P.G., Eigentler, T.K., Forschner, A., Meier, F., Garbe, C., Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit?. Melanoma Res 20 (2010), 240–246.
11. Nishino, M., Giobbie-Hurder, A., Ramaiya, N.H., Hodi, F.S., Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. J Immunother Cancer, 2(1), 2014, 40.
12. Atkins, M.B., Long, G.V., Warneke, C.L., et al. Unraveling the prognostic heterogeneity in patients with advanced melanoma between Australia (OZ) and the United States (US): preliminary report of the PHAMOUS study. J Clin Oncol, 28, 2010, 15s.
13. Peric, B., Zagar, I., Novakovic, S., Zgajnar, J., Hocevar, M., Role of serum S100B and PET-CT in follow-up of patients with cutaneous melanoma. BMC Cancer, 11, 2011, 328.
14. Francken, A.B., Bastiaannet, E., Hoekstra, H.J., Follow-up in patients with localized primary cutaneous melanoma. Lancet Oncol 6:8 (2005), 608–621.
15. Garbe, C., Paul, A., Kohler-Späth, H., et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol 21:3 (2003), 520–529.
16. Shumate, C.R., Urist, M.M., Maddox, W.A., Melanoma recurrence surveillance. Patient or physician based?. Ann Surg 221:5 (1995), 566–569 discussion 569-571.
17. Meyers, M.O., Yeh, J.J., Frank, J., et al. Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging. Ann Surg Oncol 16:4 (2009), 941–947.
18. Francken, A.B., Shaw, H.M., Accortt, N.A., Soong, S.-J., Hoekstra, H.J., Thompson, J.F., Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol 14:6 (2007), 1924–1933.
19. Poo-Hwu, W.J., Ariyan, S., Lamb, L., et al. Follow-up recommendations for patients with American Joint Committee on Cancer stages I-III malignant melanoma. Cancer 86:11 (1999), 2252–2258.
20. Ferreres, J.R., Marcoval, J., Fodge, K., de Olza, M.O., Viñals, A., Fabra, A., The utility of ancillary tests in monitoring cutaneous melanoma patients to detect visceral metastasis. J Eur Acad Dermatol Venereol 29 (2015), 2493–2495.
21. Leiter, U., Buettner, P.G., Eigentler, T.K., et al. Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German Central Malignant Melanoma Registry. J Am Acad Dermatol 66:1 (2012), 37–45.
22. Salama, A.K.S., de Rosa, N., Scheri, R.P., et al. Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy. PLoS One, 8(3), 2013, e57665.
23. Romano, E., Scordo, M., Dusza, S.W., Coit, D.G., Chapman, P.B., Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol 28:18 (2010), 3042–3047.
24. Puglisi, F., Fontanella, C., Numico, G., et al. Follow-up of patients with early breast cancer: is it time to rewrite the story?. Crit Rev Oncol Hematol 91:2 (2014), 130–141.
25. Bruinsma, S.M., Bangma, C.H., Carroll, P.R., et al. Active surveillance for prostate cancer: a narrative review of clinical guidelines. Nat Rev Urol 13 (2016), 151–167.
26. Testa, A.C., Di Legge, A., Virgilio, B., et al. Which imaging technique should we use in the follow up of gynecological cancer?. Best Pract Res Clin Obstet Gynaecol 28:5 (2014), 769–791.
27. Mundhenke, C., Moebus, V., Is symptom-oriented follow-up still up to date?. Breast Care Basel Switz 8:5 (2013), 336–340.
28. US Department of Health and Human Services. Centers for Medicare and Medicaid Services. Physician Quality Reporting System. Available from: URL: http://www.cms.hhs.gov/PQRI/. Accessed January 16, 2016.
29. Xing, Y., Bronstein, Y., Ross, M.I., et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst 103:2 (2011), 129–142.
30. Ulrich, J., van Akkooi, A.J.C., Eggermont, A.M.M., Voit, C., New developments in melanoma: utility of ultrasound imaging (initial staging, follow-up and pre-SLNB). Expert Rev Anticancer Ther 11:11 (2011), 1693–1701.
31. Weide, B., Elsässer, M., Büttner, P., et al. Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. Br J Cancer 107:3 (2012), 422–428.
32. Karagiannis, P., Fittall, M., Karagiannis, S.N., Evaluating biomarkers in melanoma. Front Oncol, 4, 2015, 383.
33. Francken, A.B., Accortt, N.A., Shaw, H.M., et al. Follow-up schedules after treatment for malignant melanoma. Br J Surg 95:11 (2008), 1401–1407.
34. Wen, J.C., Sai, V., Straatsma, B.R., McCannel, T.A., Radiation-related cancer risk associated with surveillance imaging for metastasis from choroidal melanoma. JAMA Ophthalmol 131:1 (2013), 56–61.
35. Müller-Horvat, C., Radny, P., Eigentler, T.K., et al. Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma. Eur J Cancer Oxf Engl 42:3 (2006), 342–350.
36. Fink, K.R., Fink, J.R., Imaging of brain metastases. Surg Neurol Int 4:Suppl 4 (2013), S209–S219.
37. Weide, B., Richter, S., Büttner, P., et al. Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy. PLoS One, 8(11), 2013, e81624.
38. Henry, L., Fabre, C., Guiraud, I., et al. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein; plasmatic proteasomes and malignant melanoma. Int J Cancer 133:1 (2013), 142–148.
39. Xing, Y., Cromwell, K.D., Cormier, J.N., Review of diagnostic imaging modalities for the surveillance of melanoma patients. Dermatol Res Pract, 2012, 2012, 941921.
40. Krüger, U., Kretschmer, L., Thoms, K.-M., et al. Lymph node ultrasound during melanoma follow-up significantly improves metastasis detection compared with clinical examination alone: a study on 433 patients. Melanoma Res 21:5 (2011), 457–463.
41. Pflugfelder, A., Kochs, C., Blum, A., et al. Malignant melanoma S3-guideline “diagnosis, therapy and follow-up of melanoma.”. J Dtsch Dermatol Ges 6:11 Suppl (2013), 1–116 1-126.